text:
Christ Is King but on His Term
John 6:1-21
- Mark R. Rushdoony
John 6:1-21
- Mark R. Rushdoony
Mark R. Rushdoony graduated from Los Angeles Baptist College (now The Master's College) with a B.A. in history in 1975 and was ordained to the ministry in 1995.
He taught junior and senior high classes in history, Bible, civics and economics at a Christian school in Virginia for three years before joining the staff of Chalcedon in 1978. He was the Director of Chalcedon Christian School for 14 years while teaching full time. He also helped tutor all of his children through high school.
In 1998, he became the President of Chalcedon and Ross House Books, and, more recently another publishing arm, Storehouse Press. Chalcedon and its subsidiaries publish many titles plus CDs, mp3s, and an extensive online archive at www.chalcedon.edu.
He has written scores of articles for Chalcedon's publications, both the Chalcedon Report and Faith for all of Life. He was a contributing author to The Great Christian Revolution (1991). He has spoken at numerous conferences and churches in the U.S. and abroad.
Mark Rushdoony lives in Vallecito, California, his home of 43 years with his wife of 45 years and his youngest son. He has three married children and nine grandchildren.
Keep up with Chalcedon
Subscribe for ministry news, updates, articles, and more.
By clicking Sign Up you're confirming that you agree with our Terms and Conditions.


text:
Search America's historic newspaper pages from 1770-1963 or use the U.S. Newspaper Directory to find information about American newspapers published between 1690-present. Chronicling America is sponsored jointly by the National Endowment for the Humanities external link and the Library of Congress. Learn more
Highland recorder., October 30, 1903, Image 2
About Highland recorder. (Monterey, Highland County, Va.) 1877-1972
Image provided by: Library of Virginia; Richmond, VA

subset: commoncrawl


text:
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Pragmatic Research in Healthcare Settings to Improve Kidney Disease Prevention and Care (R18)
R18 Research Demonstration and Disseminations Projects
The purpose of this Research Demonstration and Dissemination Projects (R18) Funding Opportunity Announcement (FOA) is to encourage research applications to test approaches to improve kidney disease prevention and/or treatment in routine healthcare settings. Research applications should be designed to test practical and potentially sustainable strategies that target the prevention or improved care of kidney disease, or the prevention or delay of the complications of kidney disease. The goal of the research is to obtain results that will improve routine healthcare practice and inform healthcare policy for the prevention or management of these conditions.
March 13, 2017
September 24, 2017
September 24, 2017
October 24, 2017), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Not applicable
February/March 2018
May 2018
July 2018
October 25, 2017
Not Applicable
It is critical that applicants follow the Research (R) Instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.
Part 1. Overview Information
Part 2. Full Text of the Announcement
I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information
Kidney disease is an important medical and public health problem in the U.S. The Centers for Disease Control and Prevention (CDC) estimates that over 15% of the U.S. population >20 years of age may have chronic kidney disease (CKD). The health disparities associated with CKD have been well described, including an incidence rate of End-Stage Renal Disease (ESRD) which is more than three times higher among African Americans than White Americans. A number of studies have identified the natural history (e.g., the Chronic Renal Insufficiency Cohort Study and the Chronic Kidney Disease in Children Prospective Cohort Study) and the growing burden of CKD (e.g., United States Renal Data System). Progress has been made in the identification of strategies to slow the progression of CKD, including use of specific antihypertensive ("renoprotective") drugs (angiotensin converting enzyme inhibitors or angiotensin receptor blockers), intensive glycemic control, and control of blood pressure, among others. Despite this evidence, awareness, screening, detection, prevention and treatment of kidney disease remain inadequate in the US, particularly in the ethnic and racial groups that bear a disproportionate burden of kidney disease. There is a need to test innovative and practical approaches that will reduce the burden of kidney disease by the adoption of effective approaches to prevention and treatment in daily clinical practice.
To address the growing problems of kidney disease in the nation and improve the longevity and quality of life for Americans, we must find efficient ways to translate outcomes achieved in clinical trials so that these outcomes are also achieved in routine healthcare practice. This FOA seeks research to test the effectiveness of implementation strategies for interventions in primary care settings to prevent kidney disease in at-risk individuals, increase awareness of kidney disease, improve care for individuals with kidney disease and reduce associated long term complications.
This funding announcement encourages pragmatic research designs. Pragmatic research evaluates the effectiveness of interventions or therapeutic approaches in settings designed to maximize applicability of the trial's results to routine healthcare conditions. As such, the research should leverage staff and facilities in routine and representative healthcare settings. This supports the practicality of the intervention and, if effective, approaches tested under routine conditions will have greater potential to be widely adopted.
Applications may include approaches focused on the patient, provider, healthcare team, and/or healthcare system. Studies that focus on providers may target physicians, non-physician healthcare professionals or staff within the healthcare system. Applications studying kidney disease prevention may include linkage with providers or programs outside of the clinical settings.
Areas of research focus should have the potential to generalize to other settings and types of payment and clinical practice situations. Trials that include community resources to augment healthcare are encouraged but the community resources should be well integrated into healthcare delivery. Referral to community programs or to providers outside of the clinical setting by the healthcare system or staff is not in itself, an adequate linkage. For applications that include referral to or partnership with community programs, there should also be some evidence that the community program or policy is directly linked to healthcare delivery through reimbursement and/or regular communication about patient progress and outcomes. Studies including low income/resource and diverse populations at disproportionate risk of kidney disease complications are encouraged.
Relevant topics may include but are not limited to testing:
The purpose of this FOA is to improve the care and health outcomes of individuals with kidney disease or at risk for kidney disease by improving healthcare delivery.
Interventions testing new or unapproved drugs, or interventions designed with a placebo comparison are not appropriate for this FOA.
See Section VIII. Other Information for award authorities and regulations.
Grant: A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.
The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types.
NIDDK intends to commit $1.5 million in FY 2018 to fund 3-4 awards.
Direct costs are limited to $325,000 per year.
The maximum project period is 3 years. Due to the challenges associated with implementing a pragmatic trial, it is expected that most applications will propose a project duration of three years.
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.
Higher Education Institutions
The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
Nonprofits Other Than Institutions of Higher Education
For-Profit Organizations
Non-domestic (non-U.S.) Entities (Foreign Institutions) are
not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Applicant Organizations
Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.
Program Directors/Principal Investigators (PD(s)/PI(s))
All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.
Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.
For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.
This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:
Buttons to access the online ASSIST system or to download application forms are available in Part 1 of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.
It is critical that applicants follow the Research (R) Instructions in the SF424 (R&R) Application Guide, including Supplemental Grant Application Instructions except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
For information on Application Submission and Receipt, visit Frequently Asked Questions – Application Guide, Electronic Submission of Grant Applications.
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:
The letter of intent should be sent to:
Michele Barnard, Ph.D.
Deputy Chief, Review Branch
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
6707 Democracy Boulevard, Room 751, MSC 5452
Bethesda, Maryland 20892-5452
For UPS, FedEx use 20817
Telephone: 301-594-8898
Email: email@example.com
All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.
The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing an application to this FOA.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
Research Strategy: Applications must demonstrate that the proposed intervention can be implemented within the framework of a pragmatic trial and has the potential to be widely implemented and sustained in real world clinical settings. Applications must demonstrate an interdisciplinary approach which engages healthcare system management and staff. Applications must include an approach to evaluation which includes factors pertinent to scalability and implementation including cost. Healthcare cost can be one of multiple measured endpoints or outcomes but cannot be the sole or primary endpoint that is measured.
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide:
Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
When conducting clinical research, follow all instructions for completing PHS Inclusion Enrollment Report as described in the SF424 (R&R) Application Guide.
All instructions in the SF424 (R&R) Application Guide must be followed.
See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov
Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.
Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH's electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.
Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Guidelines for Applicants Experiencing System Issues. For assistance with application submission, contact the Application Submission Contacts in Section VII.
Important reminders:
All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.
The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization's profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.
See more tips for avoiding common errors.
Applicants are required to follow the instructions for post-submission materials, as described in the policy.
Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).
Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Does the project address an important problem or a critical barrier to progress in the field? Is there a strong scientific premise for the project? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
Specific for this FOA:
Does the intervention strategy proposed have the ability to be translated into real world settings beyond the research environment, such as primary care, community, family or other patient care/support settings? Does the intervention have the potential, considering costs and healthcare practice issues, to be sustained in real world settings?
Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?
Specific for this FOA:
Do the primary outcomes proposed include objective measures of clinical status? Does the intervention involve an interdisciplinary health care team? Has the target population been clearly described in terms of age, gender race/ethnicity, and severity of kidney disease? Is the recruitment strategy consistent with a pragmatic approach? Is the sample size adequately justified? Is the data analysis plan clearly described and appropriate?
Has the investigator demonstrated appropriate partnerships with the key decision makers and staff in the healthcare setting to justify that the proposed research is feasible?
Have the researchers justified the sustainability and dissemination potential of the approach beyond the research period, including appropriate partnerships and consideration of cost and resources such as personnel and infrastructure? If so, was the plan for sustainability compelling--i.e., if successful, would these research findings be likely to improve patient outcomes in routine care settings? Is there a sufficient evaluation of the implementation costs and implementation process to meaningfully inform scalability and sustainability? This evaluation should include, where applicable, issues related to cost, reimbursement, personnel, and other resources.
If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of children, justified in terms of the scientific goals and research strategy proposed?
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.
For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.
When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
Not applicable
Not applicable
Not applicable
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.
Not applicable.
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: (1) Data Sharing Plan; (2) Sharing Model Organisms; and (3) Genomic Data Sharing Plan (GDS).
For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by National Institute of Diabetes, Digestive and Kidney Diseases, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
As part of the scientific peer review, all applications:
Appeals of initial peer review will not be accepted for applications submitted in response to this FOA.
Applications will be assigned to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the NIDDK Advisory Council. The following will be considered in making funding decisions:
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement.
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee's business official.
Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.
Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website. This includes any recent legislation and policy applicable to awards that is highlighted on this website.
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.
Recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights law. This means that recipients of HHS funds must ensure equal access to their programs without regard to a person's race, color, national origin, disability, age and, in some circumstances, sex and religion. This includes ensuring your programs are accessible to persons with limited English proficiency. HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator's scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research.
For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA. HHS provides general guidance to recipients of FFA on meeting their legal obligation to take reasonable steps to provide meaningful access to their programs by persons with limited English proficiency. Please see http://www.hhs.gov/ocr/civilrights/resources/laws/revisedlep.html. The HHS Office for Civil Rights also provides guidance on complying with civil rights laws enforced by HHS. Please see http://www.hhs.gov/ocr/civilrights/understanding/section1557/index.html; and http://www.hhs.gov/ocr/civilrights/understanding/index.html. Recipients of FFA also have specific legal obligations for serving qualified individuals with disabilities. Please see http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html. Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at http://www.hhs.gov/ocr/office/about/rgn-hqaddresses.html or call 1-800-368-1019 or TDD 1-800-537-7697. Also note it is an HHS Departmental goal to ensure access to quality, culturally competent care, including long-term services and supports, for vulnerable populations. For further guidance on providing culturally and linguistically appropriate services, recipients should review the National Standards for Culturally and Linguistically Appropriate Services in Health and Health Care at http://minorityhealth.hhs.gov/omh/browse.aspx?lvl=2&lvlid=53.
In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant's integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 "Federal awarding agency review of risk posed by applicants." This provision will apply to all NIH grants and cooperative agreements except fellowships.
Cooperative Agreement Terms and Conditions of Award
Not Applicable
When multiple years are involved, awardees will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the NIH Grants Policy Statement.
A final progress report, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement.
The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.
In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS). This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313). As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available. Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 – Award Term and Conditions for Recipient Integrity and Performance Matters.
We encourage inquiries concerning this funding opportunity
and welcome the opportunity to answer questions from potential applicants.
eRA Service Desk (Questions regarding ASSIST, eRA Commons
registration, submitting and tracking an application, documenting system problems
that threaten submission by the due date, post submission issues)
Finding Help Online: http://grants.nih.gov/support/ (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)
Customer Support (Questions
regarding Grants.gov registration and submission, downloading forms and
application packages)
Contact Center Telephone: 800-518-4726
Email: email@example.com
(Questions regarding application instructions and process, finding NIH grant
Email: email@example.com (preferred method of contact)
Telephone: 301-945-7573
Andrew S Narva, MD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-594-8864
Email: firstname.lastname@example.com
Michele L. Barnard, PhD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-594-8898
Email: firstname.lastname@example.com
Charlette L. Kenley
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-594-8847
Email: email@example.com
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75.
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.


text:
Enter your zip code
StateSelect stateAlabamaArizonaArkansasCaliforniaColoradoConnecticutDistrict of ColumbiaDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyoming
Reason for contactSelect a reason for contactNew PolicyExisting PolicyClaimsPaymentGeneral Question
Please leave this field blank in order to submit the form successfully
Thank you for submitting your request! We will contact you soon.
Thank you for your interest!
We noticed you are interested in working for an agency. You are now being redirected to IdealTraits.
If you are not redirected within 10 seconds please click here.


text:
Paula Deen cooks up $85M comeback deal
SAVANNAH, Ga. (AP) - Paula Deen has found a key ingredient to bringing some sizzle back to her career - a cash infusion worth at least $75 million from a private investment firm.
The Savannah-based celebrity cook announced Wednesday that she's launched an umbrella company that will oversee her restaurants, cookbooks, product endorsements and other remaining slices of her media empire. The new company, called Paula Deen Ventures, said private-equity firm Najafi Companies is investing $75 million to $100 million to help Deen make a comeback.
Deen's fortunes took a dive last year after comments she made under oath during proceedings in a lawsuit, namely that she had used racial slurs in the past, became public. The Food Network dropped Deen, as did pork producer Smithfield Foods, book publisher Ballantine and several other companies that paid her to endorse their products.
In a statement, Deen praised the partnership with Phoenix-based Najafi and the decision to name Steven Nanula, who has already worked with Deen for the past two years, to serve as CEO of Paula Deen Ventures.
"I know this is the right decision to lead my team, as we continue to share quality products with my fans - whose love and support have built my brands," Deen said.
Jahm Najafi, CEO of the Najafi Companies, said his firm has great respect for Deen's past success and is confident its investment will pay off. Others brands to benefit from Najafi's investments include the Phoenix Suns pro basketball team, the Book of the Month Club and SkyMall, the direct marketing business aimed at travelers.
"We know that the enterprise will be successful and valuable, as Paula and her team continue to bring quality products and experiences to her loyal fan base," Najafi said in a statement.
A publicist for Deen told The Associated Press she was not available for an interview.
Deen's image took a crushing blow last summer when a transcript of a legal deposition Deen gave to attorneys in a discrimination lawsuit filed by a former employee was made public. Deen was asked under oath if she had ever used the N-word. "Yes, of course," Deen replied, though she added: "It's been a very long time."
The lawsuit was settled out of court in August. Terms were never disclosed.


text:
Skeleton Party Hidden
Loading ... Game loaded, click here to start the game!
Thinking & Puzzle admin 09 May , 2021 0
Skeleton Party Hidden is a free online game from genre of memory and monsters truck games. Flip the tiles and try to match them up in pairs. Pair up all the tiles to win. Try to complete the game in as few moves as possible! There are is 4 levels. Use mouse to click or tap to screen on the squares. Concentrate yourself and start to play. Enjoy!
Embed this game


text:
Go to product list
See details
Required Field
Sign-up for SMS alerts to receive the latest updates and special offers.
Keep me updated with latest news.
Article 1 (Purpose)
This Agreement aims at stipulating rights, obligations and responsibilities of the Cyber Mall (hereinafter referred to as the "Mall") and the User in respect of the use of internet-related services provided by the Mall (hereinafter referred to as the "Service") in the operation of Mall. (e-commerce business).
「In addition, this Agreement shall be applied to the e-commerce using PC communication, mobile, et cetera, unless it is not against the its nature.」
Article 2 (Definition)
① "Mall" means the virtual business place on which the Company set for transacting goods and services by using information and communication facilities such as computer so that it may provide goods and services (hereinafter referred to as "Goods and Services" to the User. The term is also used as a business operating a cyber mall.
② "User" means a member or a non-member who uses Service provided by the "Mall" in accordance with this Agreement through the access to the "Mall".
③ "Member" means a person who subscribed the membership by providing his or her personal information to the "Mall", for which the member may be informed of the "Mall" on a continuous basis and use the Service offered by the "Mall".
④ "Non-Member" means a person who use the Service offered by the "Mall" not subscribing to the membership.
Article 3 (Display, Explanation & Modification of User Agreement)
① The "Mall" shall, for easier recognition by Users, display the contents of this Agreement, name of company and president, business address (including the address where customer complaints may be treated), telephone number, fax number, email address, business registration number, mail-order business registration number, staff in charge of privacy management, et cetera on the initial service page of the cyber mall. Notwithstanding the foregoing, the contents of this Agreement may be exposed to Users through a link page.
② The "Mall" shall obtain the confirmation of a User for important matters such as cancellation of purchase, delivery obligation, refund terms, et cetera through a separate link page or pop-up window before the User agrees on this Agreement so that the User may understand such important matters.
③ The "Mall" may modify this Agreement within the extent that it does not violate applicable laws, e.g. the Law related to Protection of Consumer on E-commerce, Et Cetera, the Law related to Limitation of Agreement, Basic Law of Electronic Transaction, Electronic Signature Law, the Law related to Stimulation of Use of Information and Communication Network & Information Protection, the Law related to Call Sales, Et Cetera, the Consumer Protection Law, et cetera.
④ In the event of any modification of this Agreement, the announcement stipulating the date of application and the cause of modification shall be displayed on the initial page from 7 days prior to the date of application to the previous day of the same date. Notwithstanding the foregoing, in the event that such modification becomes disadvantageous Users, such modification shall be announced at least 30 days prior to the date of application. The announcement shall include a table specifying the modification on a before-and-after basis for easier understanding of Users.
⑤ In the event of any modification of this Agreement, the modified Agreement shall be applied only to the contracts to be concluded after the date of application, whereas the provisions of this Agreement prior to the modification shall be applied to the contracts which have been previously concluded prior to the same date. Notwithstanding the foregoing, in the event that a User who already entered into the Contract sends his or her intent to be applied by the provisions of the modified Agreement to the "Mall" within the period of announcement for the modification of this Agreement in accordance with Clause ③ and acquires the approval of the "Mall", the provisions of the modified Agreement shall be applied accordingly.
⑥ The matters not stipulated herein and the interpretation of this Agreement shall be in accordance with the Law related to Protection of Consumer on E-commerce, Et Cetera, the Law related to Limitation of Agreement, the Consumer Protection Policy on E-commerce, Et Cetera stipulated by the Fair Trade Commission, and other applicable laws and commercial practices.
Article 4 (Provision & Replacement of Service)
① The "Mall" shall perform the following duties:
1. Provision of information regarding product or service and conclusion of purchase contracts
2. Delivery of product or service on purchase contract
3. Other duties designated by the "Mall"
② The "Mall" may replace product or service provided by the contract to be concluded in the event that product or service is sold out or technical specifications are changed. In this case, the "Mall" shall immediately announce the replacement of the product or service and the date of application on the page where the present product or service is displayed.
③ In the event that product or service on the contract with a User needs to be replaced because the product or service is sold out or technical specifications are changed, The "Mall" shall immediately notify the cause to the address of the User.
④ In the event of the occurrence of the previous clause, the "Mall" shall compensate the User for damages. Notwithstanding the foregoing, this shall not apply if the "Mall" proves that such event is not caused by its intention or negligence.
Article 5 (Suspension of Service)
① The "Mall" may temporarily suspend the provision of Service in the event of any repair, inspection, replacement, breakdown of information and communication equipment such as computers, or interruption of communication.
② The "Mall" shall compensate User or 3rd party for damages caused by the temporary suspension of provision of Service due to the cause(s) in Clause ①. Notwithstanding the foregoing, this shall not apply if the "Mall" proves that such event is not caused by its intention or negligence.
③ In the event of any unavailability of provision of Service due to the conversion of business item, abandon of business, integration between businesses, et cetera, the "Mall" shall notify the fact to Users in the manner stipulated in Article 8, and compensate consumers in accordance with the conditions which are initially suggested by the "Mall". Notwithstanding the foregoing, in the event that the "Mall" has not notified the criteria for compensation, the "Mall" shall pay Users for their mileage or reserve in kind or cash of which value corresponds to the currency being used at the "Mall".
Article 6 (Membership)
① The User shall apply for the membership by expressing his or her intent to agree on this Agreement after filling out the form designated by the "Mall" with the member information.
② The "Mall" shall register the User who applied for the membership in the manner stipulated in Clause ① as a Member provided that the User is not engaged in one of the following items. In the event that:
1. the applicant ever lost its membership in the past in accordance with Clause 3 of Article 7 of this Agreement. Notwithstanding the foregoing, this shall not apply to those acquired the approval of the "Mall" for re-subscription of the membership since 3 years has passed from the date of loss of membership in accordance with Clause 3 of Article 7 of this Agreement;
2. there is false information or omission in the registered contents; or
3. the "Mall" deems that the applicant may cause significant inconvenience to be registered as a Member.
③ The Membership shall be effective at the time that the Member receives the approval of the "Mall".
④ The Member shall notify any change of its information to the "Mall" in accordance with Clause 1 of Article 15 through email or other communication method.
Article 7 (Withdrawal from Membership & Loss of Eligibility)
① The Member may at any time request for the withdrawal from its membership to the "Mall", and the "Mall" shall proceed with the withdrawal on the request of the Member.
② In the event that a Member is engaged in one of the following items, the "Mall" may limit or suspend the eligibility of the Member. In the event that the Member:
1. registered false information at the time of the application for membership;
2. has not paid the price of goods it purchased through the "Mall" or other liability borne by the Member in respect of the use of the "Mall";
3. interrupts others to use the "Mall" or threats the order of e-commerce, e.g. illegal of personal information; or
4. takes any action being against the laws, this Agreement and good public order and customers by using the "Mall".
③ The "Mall" may cancel the membership of the Member whose membership was suspended or limited, and repeated the same action twice or more, or the cause is not corrected within 30 days.
④ In the event of the cancellation of membership, the "Mall" shall notify it to the Member, and give the Member 30 days or more to grant an opportunity to explain the cause prior to the cancellation.
Article 8 (Notification to Members)
① In the event of any notification of the "Mall" to a Member, it may be delivered via an email address designated by the Member through the agreement with the "Mall".
② The "Mall", in the event of the notification to unspecified Members, may replace individual notification by displaying such notification on the board linked in the website of the "Mall" for 1 week or more. Notwithstanding the foregoing, the "Mall" shall give individual notice to a Member in respect of any matter which may have a significant influence on the Member regarding his or her transaction.
Article 9 (Request for Purchase)
The User shall apply for purchase in accordance with the following manner or other similar manner at the "Mall", and the "Mall" shall provide the User with the following information in the form which the User may easily understand in his or her request for purchase. Notwithstanding the foregoing, the Member may be exempted from the application of Item 2 or Item 4 below.
1. Search and selection of goods, et cetera;
2. Entering name, address, telephone number, email address (or mobile phone number);
3. Confirmation of matter(s) in respect of the contents of this Agreement, the service(s) of which right of cancellation of purchase is limited, obligation of delivery fees and installation fees, et cetera;
4. Expression to agree on this Agreement, or confirm or refuse the Item 3 above (e.g. mouse click);
5. Application for purchase of goods and confirmation of such application, or agreement on the confirmation of the "Mall"; or
6. Selection of payment method.
Article 10 (Conclusion of Contract)
① The "Mall" may not accept the request for purchase in Article 9 if it falls one of the following items.. Notwithstanding the foregoing, in the event of the conclusion of contract with a minor, the "Mall" shall notify that the failure to acquire the agreement of the legal representative may cause the cancellation of the contract by the minor him(her)self or the legal representative. In the event that:
1. there is false information or omission in the registered contents;
2. the minor purchase any product or service restricted in the Youth Protection Law, e.g. cigarette or liquor;
3. the "Mall" deems that the applicant may cause significant inconvenience to accept the application for purchase; or
② The contract is deemed to be concluded when the acceptance of the "Mall" is delivered to the User in the form of the confirmation of receipt stipulated in Clause 1 of Article 12.
③ The acceptance of the "Mall" shall include the information such as confirmation of the application for purchase of the User, availability of sales, and correction or cancellation of the application for purchase.
Article 11 (Payment Method)
The method of payment for a product or service purchased through the "Mall" may be selected among the following items. Notwithstanding the foregoing, the "Mall" may not collect any additional fees on the amount of the product or service.
1. Account transfer, e.g. phone banking, internet banking, mail banking, et cetera;
2. card payment, e.g. prepaid card, debit card, credit card, et cetera;
3. Online non-bankbook deposit;
4. Electronic money;
5. Pay-on-receipt;
6. Point offered by the "Mall", e.g. mileage;
7. Gift voucher contracted or approved by the "Mall"; or
8. Other payment by electronic means.
Article 12 (Notice of Receipt, Change and Cancellation of Application for Purchase)
① In the event of an application for purchase of a User, the "Mall" shall notify the User with the receipt of the application.
② In the event that there is any discordance between expressions of intent, the User who received the notice of receipt may change or cancel the application for purchase immediately after the User receives the notice, and in the event of any request of a User prior to the delivery, the "Mall" shall deal with the request without any delay. Notwithstanding the foregoing, in the event that the payment has been already made, it shall be in accordance with the stipulation related to the cancellation of purchase in Article 15.
Article 13 (Provision of Goods)
① Unless otherwise stipulated herein in respect of the schedule for the provision of goods, the "Mall" shall take necessary measures to deliver the goods within 7 days from the date of purchase by a User such as customized production or packaging. Notwithstanding the foregoing, in the event that the "Mall" has received the whole or the part of the payment for the goods, such measures shall be taken within 2 business days from the date of receipt of the payment. At that time, the "Mall" shall take necessary measures to make the User check the procedures of provision of the goods and delivery process.
② The "Mall" shall specify, for the goods purchased by a User, the delivery method, payer of delivery fees by method, period of delivery by method, et cetera. In the event that the "Mall" exceeds the designated period of delivery, it shall compensate for damages to the User. Notwithstanding the foregoing, this shall not apply if the "Mall" proves that such event is not caused by its intention or negligence.
Article 14 (Refund)
In the event that the product or service which a User applied for purchase may not be provided or delivered due to sold-out or other cause, the "Mall" shall notify the situation to the User without any delay, and in the event that it has received the payment for the product or service in advance, it shall refund the payment or take necessary measures within 2 business days from the date of receipt of the payment.
Article 15 (Cancellation of Purchase)
① The User who concluded the contract for the purchase of goods with the "Mall" may cancel the purchase within 7 days from the date on which the User received the notice of receipt.
② The User may not return or change the good which he or she received through delivery in the event of one of the following items. In the event that:
1. the goods delivered is lost or damaged with the responsibility of the User (Notwithstanding the foregoing, the cancellation of purchase may be acceptable in the event of the damage on packaging for checking the contents in the box.);
2. the value of the goods is significantly decreased due to the use or consumption by the User;
3. the value of the goods is significantly decreased thus not available for re-sale due to the lapse of time;
4. the packaging is damaged, if the goods may be reproduced to the goods showing the same performance;
③ The cancellation of purchase by User shall not be limited if, in the case of Item 2 or Item 4 of Clause 2, the "Mall" did not specify the fact that the cancellation of purchase is limited for easier recognition by consumer or not take necessary measures, e.g. provision of a sample.
④ Notwithstanding Clause 1 and Clause 2, the User may cancel his or her purchase of goods within 3 months from the date of receipt of the goods or within 30 days from the date on which he or she recognized or could recognize that the contents of goods differ from the advertisement or the provision of contract.
Article 16 (Effect of Cancellation of Purchase)
① In the event of the return of goods from a User, the "Mall" shall refund the payment for the goods within 3 business days from the date on which it had received the payment. In the event that the "Mall" caused a delay of the refund to the User, it shall pay interest calculated with overdue interest rate announced by the Fair Trade Commission for the number of days of delay.
② Regarding the above-mentioned refund and in the event that the User made a payment for the goods with credit card or electronic money, the "Mall" shall request the business who provided such payment method to suspend or cancel the payment without any delay.
③ In the event of any cancellation of purchase, the User shall bear the cost for return of the goods provided. The "Mall" shall not claim for cancellation charge or compensation for damages to the User in respect of the cancellation of purchase. Notwithstanding the foregoing, in the event of the cancellation of purchase caused by that the contents of goods differ from the advertisement or the provision of contract, the "Mall" shall bear the cost for return of the goods.
④ In the event that User bore the delivery fees when he or she received the goods, the "Mall" shall specify who would bear the cost for the cancellation of purchase for easier recognition of the User.
Article 17 (Protection of Personal Information)
① The "Mall" collects minimum information necessary for the execution of the purchase contract with Users. The following items shall be necessary information and others are optional.
1. Name;
2. Address;
3. Telephone number;
4. ID (for Members);
5. Password (for Members); or
6. Email address (or mobile phone number).
② In the event that the "Mall" collects personal information available for identification of User, it must obtain the approval of the User.
③ The personal information may not be used for any purpose and provided to any 3rd party without the approval of the User, and the "Mall" shall be responsible for the matter. Notwithstanding the foregoing, it shall not apply to the following items. In the event that:
1. the "Mall" informs the delivery service provider with minimum information of User for performing delivery duty (e.g. name, address, telephone number);
2. such personal information is necessary for statistics, academic research or market research, and provided in the form that a certain individual may not be identified;
3. such personal information is necessary for the settlement of payment for transacting products, et cetera;
4. such personal information is necessary for the identification against illegal use; or
5. there is inevitable cause by regulation or law.
④ In the event that the "Mall" is required to acquire the approval of User by Clause 2 and 3, it shall specify or notify the provision stipulated in Clause of Article 22 of the Law related to Stimulation of Use of Information and Communication Network & Information Protection, e.g. identity of the personal information manager (post, name, telephone number, other contact), purpose of collection and use of information, matters related to the provision of information to 3rd party (recipient, purpose of provision and information to be provided), et cetera.
⑤ Users may at any time request for the confirmation and correction of error on their personal information possessed by the "Mall", the "Mall" shall be responsible for taking any necessary measures without any delay. In the event that a User requests for the correction of an error, the "Mall" shall not use the applicable personal information until it corrects the error.
⑥ The "Mall" shall limit the number of managers for protecting personal information, and be responsible for any damages of User caused by loss, disclosure or falsification or personal information of the User including credit card and bank account.
⑦ The "Mall" or any 3rd party who received personal information from the "Mall", shall without any delay destroy personal information after it achieves its purpose of collection of the personal information.
Article 18 (Obligations of "Mall")
① The "Mall" shall not take any action restricted by the law and this Agreement or being against the good public order and customs, and put its best efforts to provide products and services on a stable basis in accordance with the provisions in this Agreement.
② The "Mall" shall equip the security system for the protection of personal information of Users (including credit information) so that the Users may safely use online services.
③ The "Mall" shall be responsible for the compensation to User(s) if it has caused damages to the User(s) by displaying or adding unjust or unreasonable advertisement for a certain product or service in accordance with Article 3 of the Law related to Fairness of Display and Advertisement.
④ The "Mall" shall not send any profit-making emails which are not wanted by Users.
Article 19 (Obligations for ID & Password of Member)
① Each Member shall be responsible for the management of his or her ID and password, except the case in Article 17.
② Each Member shall not allow any 3rd party to use his or her ID and password.
③ In the event that a Member recognizes that his or her ID and/or password is stolen or used by a 3rd party, the Member shall immediately notify the fact to the "Mall", and follow the instruction of the "Mall", if required.
Article 20 (Obligations of User)
Users shall not:
1. register false information at the time of its application or change of information;
2. steal others' personal information;
3. change of information displayed on the "Mall";
4. remit or display any information other than the information selected by the "Mall" (computer program, et cetera);
5. infringe the copyright or the intellectual property right of the "Mall" or a 3rd party;
6. take any action to bring disgrace on or interrupt the operation of the "Mall" or a 3rd party; or
7. disclose or display any information containing indecent or violent message, video, voice, and other information being against the good public order and customs.
Article 21 (Relationship between Liking Mall & Linked Mall)
① In the event that the main mall and the sub-mall are linked with the hyperlink (e.g. the subject of hyperlink includes text, image and video), the former is called as the Linking Mall (Website) and the latter is called as the Linked Mall (Website).
② The Liking Mall shall not be responsible for any transaction with the User for any product or service independently provided by the Linked Mall if the Liking Mall specify its intent of such non-guarantee on the initial page at the website of the Liking Mall or pop-up window.
Article 22 (Copyright & Limitation of Use)
① The copyright and other intellectual property right for the works produced by the "Mall" shall be belonged to the "Mall".
② The User may not use or cause any 3rd party to use the information of which intellectual property right is belonged to the "Mall" among those acquired in the course of the use of the "Mall" for the reproduction, transmission, publishing, distribution, broadcasting or other profit-making use without the prior consent of the "Mall".
③ The "Mall" shall notify the User when using the copyright belonged to the applicable User in accordance with mutual agreement.
Article 23 (Resolution of Dispute)
① The "Mall" shall reflect the reasonable opinion or complaint made by User(s), and install and operate an organization for dealing with compensation for damages.
② The "Mall" shall give priority to any opinion or complaint made by User(s). Notwithstanding the foregoing, in the event that it may not promptly deal with the matter, the "Mall" shall notify the User with the cause and the schedule to make the treatment done.
③ In the event that there is any application for remedy by a User regarding the dispute raised between the "Mall" and the User, the matter may be treated in accordance with the settlement of the Fair Trade Commission or the arbitration commissioned by the Mayor or the jurisdiction.
Article 24 (Jurisdiction & Governing Law)
① Any and all e-commerce-related lawsuits raised between the "Mall" and a User shall be in accordance with the address of the User at that time of the suing, and in the event of there is no address, such lawsuit shall be exclusively controlled by the competent court of jurisdiction. Notwithstanding the foregoing, in the event that the address or residence of the User at that time of the suing is not clear or is not a resident of the Republic of Korea, the lawsuit shall be filed to the competent court on the Civil Procedures Code.
② Any and all e-commerce-related lawsuits raised between the "Mall" and a User shall be governed by the law of the Republic of Korea.
** Supplementary Provision (Effective Date)
This Agreement shall be effective from February 01, 2011.
I have read and agree to the user agreement. Yes
I have read and agree to the privacy policy. Yes
Do you agree to share your personal information with thired parties? Yes
Do you agree to the policies on entrusting your personal information? Yes
Cart 0 items
Company Name: PAYO International CEO: Kim Jeom Sun Business Registration No.: [608-16-10190]
E-commerce Permit No. 2008-경남마산-0079 [Mail-order Business Registration Number]
Phone: 82-10-7585-7457 Fax: Address: 51269 Kyungnam, Changwon-City, MasanHappo-gu, Kyobang-dong 365-1, Lucky villa No.505
Personal Information Manager: Kim Jeom Sun(firstname.lastname@example.com)
Contact firstname.lastname@example.com for more information.
Copyright © 2010 PAYO KOREA All rights reserved.
Please do not close this window while your order is being processed. When your payment is successfully processed this window will be closed automatically.


text:
Recipes Home
Browse Recipes
Submit a Recipe
Club + Resort Chef
reserved duck fat from duck confit
You are here
View Recipe
Cocoa-Crusted Filet Mignon
Recipe courtesy of Timothy Smith, Executive Chef, Hideaway Beach Club...
Join hundreds of your peers!
Join the Club and Resort Chef Association to network with professionals in your area, meet local vendors, gain access to educational programs and materials and more!
Join Today!
Get the Magazine!
Club + Resort Chef Digital Editions
Browse the current issue and archived issues of Club & Resort Business in an easy-to-use, high-quality format. Bookmark, share and interact with the leading club and resort magazine today.
View Latest Issue
Club+Resort Chef
Contact Us
Submit Recipe
Privacy Policy
Club & Resort Network
Club and Resort Business
Club+Resort Chef
Chef to Chef Conference
Club + Resort Chef Association
© Copyright 2023, WTWH Media LLC and its licensors. All rights reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.


text:
Help yourself to a bit of inspiration:
Peruse our embroidery catalogue for the right design.
You've been busy. Brag about it by uploading your own designs or browse what others are up to.
See more Submit your own
Visit the store nearest you:
Keeping the World Sewing
VIKING is a trademark of KSIN Luxembourg II, S.ar.l. HUSQVARNA is a trademark of Husqvarna AB. All trademarks used under license by VSM Group AB. ©2015 KSIN Luxembourg II, S.ar.l.
/Embroidery Designs/Stained Glass


text:
Our Price: $5,995
Tax, tag and title fees are not included in advertised price.
All pricing and details are believed to be accurate, but we do not warrant or guarantee such accuracy. Vehicle information is based off standard equipment and may vary from vehicle to vehicle. Call or email for complete vehicle specific information


text:
misterpattern presents you with this pattern made by Annoo Crochet with which you will learn to do a Santa Ornament step by step, in an easy and simple way.
This is a tutorial to make a lovely pattern of ornament to sew with clear and detailed explanations and also accompanied by various photos that will guide you during the creation of your work.
If you like christmas, we encourage you to not hesitate and make it since it is designed so that it can be done by both a beginner and the most advanced of the students.
But if this was not the pattern you were looking for, don't worry, we are sure that you will find it at misterpattern. You just have to keep surfing our website.
We have no doubt that you will manage to create a project equal even better than the original one. Cheer up!
Related patterns
You could like


text:
Live to Ride.
You've spent time training, taking care of, and most likely competing with your horse. And as a proud owner, it's up to you to ensure its safety and well being. Since your horse represents both a financial and emotional investment, medical expenses can be costly.
An Equine Insurance policy from Koverman Staley Dickerson Insurance Agency provides coverage for a variety of costs and expenses related to the upkeep of your animal. Our policy options include:
- Full Mortality and Theft – to insure your animals against death as a result of injury, illness, disease, humane destruction, transportation, or theft.
- Major Medical Coverage* – to provide reimbursement for the cost of medical and surgical bills caused by accident, sickness, or disease.
- Loss of Use – for compensation in the event your horse becomes totally and permanently unable to perform the duty for which it was insured.
- Stallion infertility – for coverage in the event your stallion becomes permanently incapable of producing offspring due to an accident, illness, or disease.
Finding the right coverage options for your horse doesn't have to be difficult. At Koverman Staley Dickerson Insurance Agency, one of our insurance specialists can help educate you on the different coverage options and rates available for your special animal, and together you can build the perfect policy that fits the needs of you and your horse.
*Major Medical Coverage is an addition to the Full Mortality policy and cannot be purchased alone.


text:
Kids friendly HOTSELLING pearl cluster necklace with earrings - CZ Matte Finish- Zivara Fashion
- Regular Price
- Rs. 499.00
- Sale Price
- Rs. 499.00
- Regular Price
- Unit Price
- Translation missing: en.general.accessibility.unit_price_separator
- Finish: CZ Matte
- Length: Necklace length
- Earrings included
- Shipping time
- Backrope attached
- Customisation option: No
- If status is sold , Please contact on whatsapp +91-7904637312 for restock options
Imitation jewellery needs good care of the stone and polish
Do not use perfumes
Do not drop them loose after use
Wipe them for sweat after use and replace them in a safe plastic box wrapped in a plastic cover
Remove the ropes after use.
If u prefer back chains reach out to us for additional cost details
3 to 7 business days usually for non kemp products
Kemp products are handmade on order
For kemp products,
7 to 15 business days usually.
For priority orders at extra cost pls reach out to us.
Check ur registered email for notifications and updates
Please check the spam folder as some mails redirect business emails to spam folders
We will be happy to send u the real time product proofs before shipping if u reach out to us on WhatsApp after ordering
Our couriers are insured for damages
Returns for courier damages are only encouraged. In that case unboxing videos must be provided from opening of the tamper proof grey cover with ur shipping label on it. The video must be continuous without any cuts.
For any other case we dont accept returns refunds or exchanges
For details on return/refund/exchange policy please refer our website
- By, default our products come with golden adjustable ropes.
- Microgold plated adjustable backchain will be added instead of rope, if the checkbox is selected
- Rs 50 is additional
- Length : 9 inches.
- When there are multiple neckwears in the order , the chain will be added to the product with highest cost .
- In case of combos, back chain will be added to the long neckwear.


text:
MCM SCX Plus
Your email address will not be published. Required fields are marked *
Comment *
Prodecoder ® tools are manufactured and assembled in Sofia, Bulgaria. All of our products are ORIGINAL – invented and produced by team of engineers that guarantee the quality and durability of our locksmith tools and kits. Here you will find car locksmith tools for emergency opening and also home locksmith tools. Our products serve professionals all around the world. We make your job easier.
Prodecoder® is an original European registered trademark © 2023 All Rights Reserved
We use cookies to ensure that we give you the best experience on our website. Click here for more information.


text:
Skip Quicknav
Debian Quality Assurance
Maintainer page
Back to the Debian Project homepage.
To report a problem with the QA web site, file a bug on the
qa.debian.org pseudo-package,
or e-mail firstname.lastname@example.com.
For other contact information, see the Debian contact page.
Made by Igor Genibel, Christoph Berg, and others.
Last generated on Tue Jan 8 15:26:03 2019 UTC
Copyright © 1997-2015
SPI; See license terms
Debian is a registered trademark of Software in the Public Interest, Inc.


text:
Francisco Bastos Ranking (POR)
Country: Portugal, Category: Junior, Boys
Profile | Ranking | Results | Statistics
No ITF Junior or Professional ranking for Francisco Bastos.
Discover all of last week's tournament winners from all age groups and tier levels - on our signature single page format.
If you are a player featured in CoreTennis, you can get in touch with us to have more information and your pictures published on your profile